Abbott: A Dividend King’s Quiet Resilience

Abbott’s recent pronouncements regarding its fourth quarter did not, apparently, meet with the breathless enthusiasm the market demands. Sales of $11.5 billion, a modest increase of 4.4%, were deemed insufficient. Nutrition and diagnostics, it seems, experienced a slight… hesitation. One might say they lacked a certain joie de vivre. The guidance for 2026 was equally underwhelming. The stock responded accordingly. It’s a curious thing, this insistence on immediate gratification. One would think investors had forgotten the virtues of patience.








